| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Sanofi | SARCLISA (isatuximab) - (IMROZ) | Multiple myeloma not eligible for transplant | Phase 3 | Ongoing | Intravenous | Oncology |
| Sanofi | DUPIXENT (dupilumab) - (CUPID STUDY C) | Chronic Spontaneous Urticaria (CSU) | Phase 3 | Data Released | Subcutaneous | Immunology |
| Sanofi | KEVZARA (sarilumab) | Coronavirus COVID-19 | Phase 3 | Trial Discontinued | Subcutaneous | COVID-19 |
| Sanofi | KEVZARA (sarilumab) | Coronavirus COVID-19 | Phase 3 | Trial Discontinued | Subcutaneous | COVID-19 |
| Sanofi | LIBTAYO (cemiplimab) | Non-small cell lung cancer (NSCLC) | Phase 3 | Trial Discontinued | intravenous | Oncology |
| Sanofi | Amcenestrant - (AMEERA-5) | ER+/HER2- advanced breast cancer | Phase 3 | Trial Discontinued | Oral | Oncology |
| Sanofi | PRV-031 (teplizumab) - (PROTECT) | Recent Onset Type 1 Diabetes | Phase 3 | Ongoing | Intravenous | Endocrinology |
| Sanofi | SARCLISA (isatuximab) - (IMROZ) | Multiple myeloma not eligible for transplant | Phase 3 | Ongoing | Intravenous | Oncology |